RT Journal Article
SR Electronic
T1 Untargeted Metabolomics of Breast Cancer Cells MCF-7 and SkBr3 Treated With Tamoxifen/Trastuzumab
JF Cancer Genomics - Proteomics
JO Cancer Genomics Proteomics
FD International Institute of Anticancer Research
SP 79
OP 93
DO 10.21873/cgp.20305
VO 19
IS 1
A1 BASMA M. SHARAF
A1 ALEXANDER D. GIDDEY
A1 HASAN ALNISS
A1 HAMZA M. AL-HROUB
A1 RAAFAT EL-AWADY
A1 MUATH MOUSA
A1 AHMED ALMEHDI
A1 NELSON C. SOARES
A1 MOHAMMAD H. SEMREEN
YR 2022
UL http://cgp.iiarjournals.org/content/19/1/79.abstract
AB Background/Aim: Trastuzumab and tamoxifen are two of the most widely prescribed anti-cancer drugs for breast cancer (BC). To date, few studies have explored the impact of anticancer drugs on metabolic pathways in BC. Metabolomics is an emerging technology that can identify new biomarkers for tracking therapy response and novel therapeutic targets. Materials and Methods: We employed ultra-high-performance liquid chromatography-quadrupole time of flight mass spectrometry (UHPLC-QTOF-MS) to investigate changes in MCF-7 and SkBr3 cell lines treated with either tamoxifen, trastuzumab or a combination of both. The Bruker Human Metabolome Database (HMDB) metabolite library was used to match spectra and the MetaboScape software to assign each feature with a putative metabolite name or molecular formula for metabolite annotation. Results: A total of 98 metabolites were found to significantly differ in abundance in MCF-7 and SkBr3 treated cells. Moreover, the metabolic profile of the combination medication is similar to that of tamoxifen alone, according to functional enrichment analysis. Conclusion: Tamoxifen/trastuzumab treatment had a significant effect on pathways essential for the control of energy-production, which have previously been linked to cancer progression, and aggressiveness